Skip to main content
ACS Medicinal Chemistry Letters logoLink to ACS Medicinal Chemistry Letters
. 2026 Sep 3;17(10):2270–2271. doi: 10.1021/acsmedchemlett.6c00463

Correction to “Discovery of a Colon-Targeted Prodrug As an Escherichia coli Biofilm Inhibitor for Treating Inflammatory Bowel Disease”

Takahisa Shimizu ✉, Keiko Tago, Miki Yokoyama, Koichi Nakamura, Sumika Tokieda-Tanoue, Akemi Kita, Shojiro Miyazaki
PMCID: PMC13656287  PMID: 42865975

This Correction addresses errors in the Conflict of Interest (COI) statement, Funding Information, and a pH value related to the permeability measurement published in the original article.

  • 1.

    Correction to the Conflict of Interest (COI) statement and Funding Information

    The corrected COI statement and Funding Information are as follows:

    Notes The authors declare the following competing financial interest(s): All authors are employees of Daiichi Sankyo Co., Ltd. and may own stock in the company.

    Funding This work was supported by Daiichi Sankyo Co., Ltd.

  • 2.

    Correction to the pH value in the permeability measurement

In the original article, the pH value used in the permeability measurement was incorrectly stated as pH 5.5 in Table . The correct pH value is pH 5.0.

3. ADMET Results (Solubility/Permeability/Metabolic Stability) and Fecal Excretion Ratio in PK Study.

graphic file with name ml6c00463_0001.webp


Articles from ACS Medicinal Chemistry Letters are provided here courtesy of American Chemical Society

RESOURCES